Items where Author is "Alt, J."

Conference or Workshop Item

Faehling, M. and Schumann, C. and Christopoulos, P. and Hoffknecht, P. and Alt, J. and Horn, M. and Eisenmann, S. and Schlenska-Lange, A. and Aries, S. P. and Sackmann, S. and Schuett, P. and Steger, F. and Christoph, D. (2020) Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). In: ESMO Virtual Congress, SEP 19-OCT 18, 2020, ELECTR NETWORK.

Schulz, C. and Chen, Y. and Paz-Ares, L. G. and Dvorkin, M. and Trukhin, D. and Reinmuth, N. and Garassino, M. C. and Statsenko, G. and Voitko, O. and Hochmair, M. J. and Ozguroglu, M. and Verderame, F. and Havel, L. and Losonczy, G. and Conev, N. and Hotta, K. and Ji, J. H. and Broadhurst, H. and Byrne, N. and Thiyagarajah, P. and Goldman, J. W. and Alt, J. (2020) First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes. In: Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020, Virtuell.

Other

Alt, J. and Bischoff, H. G. and Laack, H-E and Leistner, R. D. and Panse, J. and Reinmuth, N. and Schulz, C. and Grohe, C. (2018) A Phase 3, randomized study of first-line durvalumab (D) plus /- tremelimumab (T) plus platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): CASPIAN. KARGER, BASEL.